氨鲁米特治疗晚期乳腺癌——先前接受他莫昔芬治疗后的反应
Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment.
作者信息
Bezwoda W R, Derman D P, Browde S, Goss G, Lange M
出版信息
S Afr Med J. 1984 Sep 8;66(10):372-4.
Thirty-one postmenopausal patients with advanced breast cancer either unresponsive to tamoxifen or progressing after responding to tamoxifen were treated with aminoglutethimide (1 000 - 1 250 mg/d) plus hydrocortisone replacement. The response rate was 33% in patients who had never responded to tamoxifen and 47% in patients who had previously responded to tamoxifen. The overall response rate was 42%. These results show that aminoglutethimide is an effective second-line hormonal treatment for patients with advanced breast cancer.
31例绝经后晚期乳腺癌患者，对他莫昔芬无反应或在对他莫昔芬产生反应后病情进展，接受氨鲁米特（1000 - 1250毫克/天）加氢化可的松替代治疗。从未对他莫昔芬有反应的患者缓解率为33%，先前对他莫昔芬有反应的患者缓解率为47%。总缓解率为42%。这些结果表明，氨鲁米特是晚期乳腺癌患者有效的二线激素治疗药物。
Zotero 插件